Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Department of Ultrasound, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Bosn J Basic Med Sci. 2022 Oct 23;22(6):862-871. doi: 10.17305/bjbms.2022.7343.
Papillary thyroid carcinoma (PTC) is the most common form of thyroid cancer. Several studies have proposed serum microRNAs (miRNAs) as novel biomarkers for diagnosing PTC. In this study, we conducted a meta-analysis aiming to investigate the overall diagnostic accuracy of serum miRNAs in PTC detection. Three online databases including PubMed, EMBASE and Cochrane Library were searched up to 1 May 2021. We systematically reviewed studies evaluating the value of serum miRNAs in diagnosing PTC, and then summarized the area under receiver operating characteristics curve (AUROC), sensitivity, specificity, and diagnostic odds ratio to assess the accuracy of serum miRNAs for the discrimination between patients with PTC and patients with benign thyroid nodules and healthy controls. We included 32 studies from 6 articles. Overall, there were 463 PTC patients, 334 patients with benign thyroid nodules, and 104 healthy controls. The results showed that the summary sensitivity and specificity were 76% (95% confidence interval [CI]: 68%‒83%) and 86% (95% CI: 80%‒91%), respectively, and that the summary AUROC was 0.89 (95% CI: 0.86‒0.91), when serum miRNAs were used for discriminating between PTC patients and those with benign nodules. On the other hand, the summary sensitivity and specificity of serum miRNAs for discriminating between PTC patients and healthy controls were 82% (95% CI: 77%‒86%) and 84% (95% CI: 76%‒90%), respectively, and the summary AUROC was 0.89 (95% CI: 0.86‒0.92). We found that serum miRNAs have good diagnostic performance for the discrimination between patients with PTC and patients with benign nodules and healthy controls, and thus have considerable potential as novel minimally invasive tools for detecting PTC.
甲状腺癌（PTC）是最常见的甲状腺癌类型。几项研究提出了血清 microRNAs（miRNAs）作为诊断 PTC 的新型生物标志物。在这项研究中，我们进行了一项荟萃分析，旨在研究血清 miRNAs 对 PTC 检测的总体诊断准确性。我们搜索了 PubMed、EMBASE 和 Cochrane Library 这三个在线数据库，截至 2021 年 5 月 1 日。我们系统地回顾了评估血清 miRNAs 在诊断 PTC 中的价值的研究，然后总结了受试者工作特征曲线下的面积（AUROC）、敏感性、特异性和诊断优势比，以评估血清 miRNAs 用于区分 PTC 患者与良性甲状腺结节患者和健康对照者的准确性。我们纳入了来自 6 篇文章的 32 项研究。总体而言，共有 463 名 PTC 患者、334 名良性甲状腺结节患者和 104 名健康对照者。结果表明，汇总敏感性和特异性分别为 76%（95%置信区间：68%83%）和 86%（95%置信区间：80%91%），当使用血清 miRNAs 区分 PTC 患者和良性结节患者时，汇总 AUROC 为 0.89（95%置信区间：0.860.91）。另一方面，血清 miRNAs 用于区分 PTC 患者和健康对照者的汇总敏感性和特异性分别为 82%（95%置信区间：77%86%）和 84%（95%置信区间：76%90%），汇总 AUROC 为 0.89（95%置信区间：0.860.92）。我们发现，血清 miRNAs 对区分 PTC 患者和良性结节患者和健康对照者具有良好的诊断性能，因此作为检测 PTC 的新型微创工具具有相当大的潜力。
